Greetings, and welcome to the HeartBeam Fourth Quarter 2025 Financial Results Conference Call. [Operator Instructions]. As a reminder, today's conference is being recorded. Before we begin the formal presentation, I would like to remind everyone that ...

HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New

(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio (TM), a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs.

HeartBeam, Inc. BEAT shares are trading higher Tuesday after the company announced a strategic partnership with Mount Sinai to accelerate the joint development and validation of next-generation AI-ECG algorithms.

HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. Management will host a presentation webcast on March 16 at 11:20 a.m. Eastern time (8:20 a.m. Pacific time) and host one-on-one meetings with institutional and retail investors.

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through advanced cardiac

SANTA CLARA, Calif.--(BUSINESS WIRE)--HeartBeam, Inc. (NASDAQ: BEAT), a cardiac technology company that has developed the first and only 3D vector electrocardiogram (VECG) platform intended for patient use at home, today announced it has received a notice ...

(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms.

HeartBeam (NASDAQ:BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai aimed at accelerating the development and clinical validation of next-generation artificial intelligence ECG algorithms.

HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings ALIGN-ACS study expected to complete patient enrollment quickly Milestone signifies key step toward future FDA indication expansion for heart attack assessment Future indication expansion would unlock large market with over 20

Brian Humbarger, our new Chief Commercial Officer, will provide an overview of our limited commercial launch. Before we dive into updates since our last call in November, I want to remind everyone about our initial product,